NeuroBo Pharma Files Routine 8-K, Updates Corporate Info
Ticker: MTVA · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-update, 8-K
TL;DR
**NeuroBo Pharma filed a routine 8-K, no new material news.**
AI Summary
NeuroBo Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, to update its general corporate information, including its business address at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138, and its telephone number (857) 702-9600. This filing is a routine update and does not contain any new material financial or operational information. For investors, this means there are no immediate changes to the company's strategic direction or financial health indicated by this specific filing, so it should not significantly impact stock ownership decisions.
Why It Matters
This filing is a standard administrative update, providing current contact and registration details for NeuroBo Pharmaceuticals, Inc. It does not contain any new financial or operational news that would typically move the stock.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not introduce any new financial, operational, or strategic risks to the company.
Analyst Insight
Given this is a routine administrative filing with no new material information, a smart investor would likely take no immediate action based solely on this 8-K. It confirms the company's current contact details but offers no insights into its financial performance or strategic direction.
Key Numbers
- January 18, 2024 — Filing Date (The date the 8-K was filed and the earliest event reported.)
- 001-37809 — SEC File Number (The unique identifier for NeuroBo Pharmaceuticals, Inc.'s filings with the SEC.)
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- January 18, 2024 (date) — date of the earliest event reported and filing date
- 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138 (address) — principal executive offices of NeuroBo Pharmaceuticals, Inc.
- (857) 702-9600 (phone_number) — registrant's telephone number
- Delaware (state) — state of incorporation for NeuroBo Pharmaceuticals, Inc.
- 001-37809 (string) — Commission File Number
- 47-2389984 (string) — IRS Employer Identification No.
- NRBO (string) — Trading Symbol for Common Stock
- The Nasdaq Stock Market LLC (string) — exchange where Common Stock is registered
- $0.001 (dollar_amount) — par value per share of Common Stock
FAQ
What is the purpose of this 8-K filing by NeuroBo Pharmaceuticals, Inc.?
This 8-K filing by NeuroBo Pharmaceuticals, Inc. is a routine administrative update, primarily to report 'Other Events' and 'Financial Statements and Exhibits' as of January 18, 2024, without disclosing any new material financial or operational information.
What is the current business address and phone number of NeuroBo Pharmaceuticals, Inc. as stated in the filing?
According to the filing, the current business address of NeuroBo Pharmaceuticals, Inc. is 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138, and its telephone number is (857) 702-9600.
What is the trading symbol and the exchange where NeuroBo Pharmaceuticals, Inc.'s common stock is registered?
The common stock of NeuroBo Pharmaceuticals, Inc. trades under the symbol NRBO and is registered on The Nasdaq Stock Market LLC.
What is the state of incorporation for NeuroBo Pharmaceuticals, Inc.?
NeuroBo Pharmaceuticals, Inc. is incorporated in Delaware, as stated in the filing.
Does this 8-K filing contain any information about new financial statements or exhibits?
While the 'ITEM INFORMATION' section lists 'Financial Statements and Exhibits,' the body of this specific 8-K filing (nrbo-20240118x8k.htm) does not contain any new financial statements or exhibits, indicating it's a placeholder or a general category for the filing type rather than a disclosure of new financial data.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-01-18 08:30:23
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240118x8k.htm (8-K) — 42KB
- nrbo-20240118xex99d1.htm (EX-99.1) — 19KB
- nrbo-20240118x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240118xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-000351.txt ( ) — 231KB
- nrbo-20240118.xsd (EX-101.SCH) — 3KB
- nrbo-20240118_lab.xml (EX-101.LAB) — 15KB
- nrbo-20240118_pre.xml (EX-101.PRE) — 9KB
- nrbo-20240118x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 18, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") issued a press release announcing positive pre-clinical safety data of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in combination with sitagliptin, a DPP4 inhibitor. Additionally, having satisfied its 45-day commitment with the U.S. Food and Drug Administration (FDA) related to its amended protocol, the Company has opened enrollment for Part 2 of its Phase 2a clinical trial of DA-1241 when co-administered with sitagliptin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated January 18, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: January 18, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer